- Home
- PCRX vs PML Comparison
PCRX vs PML Comparison
Compare PCRX & PML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- PML
- Stock Information
- Founded
- PCRX 2006
- PML 2002
- Country
- PCRX United States
- PML United States
- Employees
- PCRX N/A
- PML N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- PML Investment Managers
- Sector
- PCRX Health Care
- PML Finance
- Exchange
- PCRX Nasdaq
- PML Nasdaq
- Market Cap
- PCRX 1.2B
- PML 508.5M
- IPO Year
- PCRX 2011
- PML N/A
- Fundamental
- Price
- PCRX $22.90
- PML $7.35
- Analyst Decision
- PCRX Buy
- PML
- Analyst Count
- PCRX 8
- PML 0
- Target Price
- PCRX $28.38
- PML N/A
- AVG Volume (30 Days)
- PCRX 545.0K
- PML 188.0K
- Earning Date
- PCRX 07-29-2025
- PML 01-01-0001
- Dividend Yield
- PCRX N/A
- PML 5.65%
- EPS Growth
- PCRX N/A
- PML N/A
- EPS
- PCRX N/A
- PML N/A
- Revenue
- PCRX $702,772,000.00
- PML N/A
- Revenue This Year
- PCRX $7.54
- PML N/A
- Revenue Next Year
- PCRX $10.78
- PML N/A
- P/E Ratio
- PCRX N/A
- PML N/A
- Revenue Growth
- PCRX 3.08
- PML N/A
- 52 Week Low
- PCRX $11.16
- PML $6.92
- 52 Week High
- PCRX $27.64
- PML $9.46
- Technical
- Relative Strength Index (RSI)
- PCRX 35.82
- PML 47.28
- Support Level
- PCRX $22.82
- PML $7.39
- Resistance Level
- PCRX $23.83
- PML $7.45
- Average True Range (ATR)
- PCRX 0.74
- PML 0.06
- MACD
- PCRX -0.02
- PML 0.01
- Stochastic Oscillator
- PCRX 6.22
- PML 70.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About PML Pimco Municipal Income Fund II of Beneficial Interest
PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.